RecruitingNCT06382987

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan

Sponsor

Bristol-Myers Squibb

Enrollment

600 participants

Start Date

Jan 22, 2024

Study Type

OBSERVATIONAL

Conditions

Plaque Psoriasis

Summary

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Japanese adult participants aged 18 years old or older
Physician-reported diagnosis of plaque psoriasis
Newly initiating deucravacitinib or apremilast according to the label
Participants who have signed informed consent

Exclusion Criteria3

Participants currently participating in or planning to participate in an interventional clinical trial
Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)

Interested in this trial?

Get notified about updates and connect with the research team.